Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Farhad Ravandi, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Charles Asa Koller, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Elizabeth M Burton, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 3617.

https://doi.org/10.1182/blood.V120.21.3617.3617

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

Journal Articles

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Kiran Naqvi, MD, Hagop M Kantarjian, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, Susan O'Brien, MD, Elizabeth M Burton, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Gautam Borthakur, Alfonso Quintas-Cardama, MD, Jorge E. Cortes

Blood (2011) 118 (21): 3784.

https://doi.org/10.1182/blood.V118.21.3784.3784

Published: 2011

Journal Articles

Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,

Asifa Malik, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan o'Brien, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Deborah A. Thomas, MD, Elizabeth M Burton, Elias Jabbour, Jorge E. Cortes

Blood (2011) 118 (21): 3786.

https://doi.org/10.1182/blood.V118.21.3786.3786

Published: 2011

Journal Articles

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Maro Ohanian, DO, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Elizabeth M Burton, Long Xuan Trinh, Alessandra Ferrajoli, MD, Elias Jabbour, Tapan Kadia, Jorge E. Cortes

Blood (2011) 118 (21): 3779.

https://doi.org/10.1182/blood.V118.21.3779.3779

Published: 2011

Journal Articles

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, MD, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O’Brien, Jorge E. Cortes

Blood (2011) 118 (21): 4443.

https://doi.org/10.1182/blood.V118.21.4443.4443

Published: 2011

Journal Articles

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Theresa Liu-Dumlao, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Elias Jabbour, Jan A. Burger, MD, PhD, Yesid Alvarado, MD, Elizabeth M Burton, Long Xuan Trinh, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 2761.

https://doi.org/10.1182/blood.V118.21.2761.2761

Published: 2011

Journal Articles

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, MD, Elizabeth M Burton, Gautam Borthakur, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Marina Konopleva, M.D., Ph.D., Jan A. Burger, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 745.

https://doi.org/10.1182/blood.V118.21.745.745

Published: 2011

Journal Articles

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O'Brien, Jorge E Cortes

Blood (2011) 118 (21): 2764.

https://doi.org/10.1182/blood.V118.21.2764.2764

Published: 2011

Journal Articles

Stomatin-deficient cryohydrocytosis results from mutations in SLC2A1 : a novel form of GLUT1 deficiency syndrome

Joanna F. Flatt, Hélène Guizouarn, Nicholas M. Burton, Franck Borgese, Richard J. Tomlinson, Robert J. Forsyth, Stephen A. Baldwin, Bari E. Levinson, Philippe Quittet, Patricia Aguilar-Martinez, Jean Delaunay, Gordon W. Stewart, Lesley J. Bruce

Blood (2011) 118 (19): 5267–5277.

https://doi.org/10.1182/blood-2010-12-326645

Published: 2011

Includes: Supplemental data

Journal Articles

Mutations in the second zinc finger of human EKLF reduce promoter affinity but give rise to benign and disease phenotypes

Belinda K. Singleton, Winnie Lau, Victoria S. S. Fairweather, Nicholas M. Burton, Marieangela C. Wilson, Steve F. Parsons, Ben M. Richardson, Kongtana Trakarnsanga, R. Leo Brady, David J. Anstee, Jan Frayne

Blood (2011) 118 (11): 3137–3145.

https://doi.org/10.1182/blood-2011-04-349985

Published: 2011

Includes: Supplemental data

Journal Articles

A Novel EKLF Mutation in a Patient with Dyserythropoietic Anemia: The First Association of EKLF with Disease in Man.

Belinda K Singleton, Victoria SS Fairweather, Winnie Lau, Stephen F Parsons, Nicholas M Burton, Jan Frayne, R. Leo Brady, David J Anstee

Blood (2009) 114 (22): 162.

https://doi.org/10.1182/blood.V114.22.162.162

Published: 2009

Journal Articles

Hematologic and Hospitalization Outcomes in Patients with Chemotherapy-Induced Anemia (CIA) Treated with Erythropoiesis-Stimulating Agents (ESAs) in the Pre- Vs Post-National Coverage Determination (NCD) Time Periods.

Elizabeth Apgar, MPH, Tanya M. Burton, PhD, Kay Larholt, ScD, Chris L. Pashos, PhD, Lorie Ellis, PhD, Mekré Senbetta, PharmD, R. Scott McKenzie, MD

Blood (2009) 114 (22): 2482.

https://doi.org/10.1182/blood.V114.22.2482.2482

Published: 2009

Journal Articles

The monovalent cation leak in overhydrated stomatocytic red blood cells results from amino acid substitutions in the Rh-associated glycoprotein

Lesley J. Bruce, Hélène Guizouarn, Nicholas M. Burton, Nicole Gabillat, Joyce Poole, Joanna F. Flatt, R. Leo Brady, Franck Borgese, Jean Delaunay, Gordon W. Stewart

Blood (2009) 113 (6): 1350–1357.

https://doi.org/10.1182/blood-2008-07-171140

Published: 2009

Includes: Supplemental data

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, Gautam Borthakur, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William G. Wierda, Elizabeth M Burton, Jorge Cortes

Blood (2008) 112 (11): 2111.

https://doi.org/10.1182/blood.V112.11.2111.2111

Published: 2008

Journal Articles

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Dushyant Verma, MD, FACP, Hagop M. Kantarjian, MD, Mary Beth Rios, Susan O’Brien, MD, Pat Ault, Elizabeth M. Burton, Zeev Estrov, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Jorge Cortes, MD

Blood (2008) 112 (11): 2125.

https://doi.org/10.1182/blood.V112.11.2125.2125

Published: 2008

Journal Articles

Mutations in EKLF / KLF1 form the molecular basis of the rare blood group In(Lu) phenotype

Belinda K. Singleton, Nicholas M. Burton, Carole Green, R. Leo Brady, David J. Anstee

Blood (2008) 112 (5): 2081–2088.

https://doi.org/10.1182/blood-2008-03-145672

Published: 2008

Includes: Supplemental data

Journal Articles

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Jeffrey Lancet, MD, Maria R. Baer, MD, Ivana Gojo, MD, M. Burton, M. Quinn, S.M. Tighe, Kapil Bhalla, MD, K. Kersey, S. Wells, Z. Zhong, PhD, B. Sadler, Maher Albitar, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS

Blood (2006) 108 (11): 1961.

https://doi.org/10.1182/blood.V108.11.1961.1961

Published: 2006

NARROW

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Stomatin-deficient cryohydrocytosis results from mutations in SLC2A1 : a novel form of GLUT1 deficiency syndrome

Mutations in the second zinc finger of human EKLF reduce promoter affinity but give rise to benign and disease phenotypes

A Novel EKLF Mutation in a Patient with Dyserythropoietic Anemia: The First Association of EKLF with Disease in Man.

Hematologic and Hospitalization Outcomes in Patients with Chemotherapy-Induced Anemia (CIA) Treated with Erythropoiesis-Stimulating Agents (ESAs) in the Pre- Vs Post-National Coverage Determination (NCD) Time Periods.

The monovalent cation leak in overhydrated stomatocytic red blood cells results from amino acid substitutions in the Rh-associated glycoprotein

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Mutations in EKLF / KLF1 form the molecular basis of the rare blood group In(Lu) phenotype

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only